Characteristics of hematologic malignancy patients with URTI or LRTI and pandemic (H1N1) 2009 virus, University of California, San Francisco, Medical Center, San Francisco, California, USA, June-December 2009 * Total, URTI, Characteristic n = 27 n = 17 Median age, y (range) 43 (5-83) 33 (5-83) Male sex 18 (67) 10 (59) Underlying malignancy Acute lymphocytic leukemia 6 (22) 5 (29) Acute myelocytic
leukemia 5 (19) 4 (24) Chronic lymphocytic leukemia 1 (4) 1 (6) Lymphoma 6 (22) 2 (12) Multiple myeloma 7 (26) 4 (24) Other 2 (7) 1 (6) Hematopoietic cell transplant 18 (67) 12 (71) Allogeneic 7 (39) 4 (33) Graft-vs.
Patient #17: In April 1977, after developing a scrotal abscess and significant anemia requiring transfusion, Patient #17 was diagnosed at the Ochsner Clinic in New Orleans with acute myelocytic
leukemia, confirmed by bone marrow biopsy.
Three years ago, after a blood test before a bunion operation on her right foot, she eventually found out she had acute myelocytic
leukemia, an aggressive, fast-moving from of the blood cancer.
differentiation can take place in the presence of pharmacological rather than physiological levels of ATRA.
Unique genetic alterations in combinations or in isolation account for a small fraction of MDS suggesting the epigenetic hypermethylation as a possible leading cause for MDS and its transformation to acute myelocytic
Abstract: Granulocytic sarcomas, also known as chloromas, are rare extramedullary tumors of myeloid or myelocytic
leukemia-Part II: Approaches to and molecular monitoring of therapy.
Significant tumor response to Hydrea has been demonstrated in melanoma, resistant chronic myelocytic
leukemia; and recurrent, metastatic, or inoperable carcinoma of the ovary.
Initially approved in 2001, Glivec, a single transduction inhibitor, is now available in over 80 countries worldwide and is indicated for the treatments of chronic myelocytic
leukemia and gastrointestinal stromal tumor.
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic
s Cytosar-U and is indicated for remission induction in certain cases of patients with acute lymphocytic leukemia and chronic myelocytic
Detection of BCR-ABL gene rearrangement and the elimination of rearranged clone in chronic myelocytic